10974184

Source:http://linkedlifedata.com/resource/pubmed/id/10974184

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0016011, umls-concept:C0021149, umls-concept:C0087111, umls-concept:C0151699, umls-concept:C0205164, umls-concept:C0243077, umls-concept:C0597357, umls-concept:C0936012, umls-concept:C1522701, umls-concept:C1709595, umls-concept:C2349200
pubmed:issue	3
pubmed:dateCreated	2000-10-5
pubmed:abstractText	The major risk of therapy with platelet glycoprotein IIb/IIIa receptor inhibitors is bleeding. We reviewed trials using these agents to determine if bleeding risks include an increased incidence of intracranial hemorrhage.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0267200
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Acetates, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Anticoagulants, http://linkedlifedata.com/resource/pubmed/chemical/Heparin, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Fab Fragments, http://linkedlifedata.com/resource/pubmed/chemical/Peptides, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Glycoprotein GPIIb-IIIa..., http://linkedlifedata.com/resource/pubmed/chemical/Tyrosine, http://linkedlifedata.com/resource/pubmed/chemical/abciximab, http://linkedlifedata.com/resource/pubmed/chemical/eptifibatide, http://linkedlifedata.com/resource/pubmed/chemical/lamifiban, http://linkedlifedata.com/resource/pubmed/chemical/tirofiban
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	0002-9343
pubmed:author	pubmed-author:BlankenshipJ CJC, pubmed-author:FreyC MCM, pubmed-author:MemonM AMA, pubmed-author:MenapaceF JFJ, pubmed-author:WoodG CGC
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	109
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	213-7
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:10974184-Acetates, pubmed-meshheading:10974184-Acute Disease, pubmed-meshheading:10974184-Angioplasty, Balloon, Coronary, pubmed-meshheading:10974184-Antibodies, Monoclonal, pubmed-meshheading:10974184-Anticoagulants, pubmed-meshheading:10974184-Coronary Disease, pubmed-meshheading:10974184-Drug Therapy, Combination, pubmed-meshheading:10974184-Heparin, pubmed-meshheading:10974184-Humans, pubmed-meshheading:10974184-Immunoglobulin Fab Fragments, pubmed-meshheading:10974184-Incidence, pubmed-meshheading:10974184-Infusions, Intravenous, pubmed-meshheading:10974184-Intracranial Hemorrhages, pubmed-meshheading:10974184-Odds Ratio, pubmed-meshheading:10974184-Peptides, pubmed-meshheading:10974184-Platelet Aggregation Inhibitors, pubmed-meshheading:10974184-Platelet Glycoprotein GPIIb-IIIa Complex, pubmed-meshheading:10974184-Randomized Controlled Trials as Topic, pubmed-meshheading:10974184-Syndrome, pubmed-meshheading:10974184-Tyrosine
pubmed:year	2000
pubmed:articleTitle	Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.
pubmed:affiliation	Geisinger Medical Center, and the Janet Weis Research Center, Danville, Pennsylvania, USA.
pubmed:publicationType	Journal Article, Meta-Analysis